Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BRISTOL MYERS SQUIBB CO

Get SEC filing alerts via email and in your feed for BRISTOL MYERS SQUIBB CO

BMY BMYMP CELG-RI

BRISTOL MYERS SQUIBB CO

About BRISTOL MYERS SQUIBB CO

Bristol-Myers Squibb Company is a global biopharmaceutical firm focused on discovering, developing, manufacturing, and marketing innovative medicines. Its core therapeutic areas include oncology, hematology, immunology, cardiovascular, and neuroscience. The company offers a portfolio of biologics, small molecules, and cell therapies, serving healthcare providers, wholesalers, specialty pharmacies, and hospitals worldwide. Its competitive advantage lies in combining pharmaceutical scale with biotech innovation to deliver transformational treatments for serious diseases.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BRISTOL MYERS SQUIBB CO

1
1
BRISTOL MYERS SQUIBB CO Bristol-Myers Squibb Reports 3% Revenue Growth to $11.489 Billion in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
BRISTOL MYERS SQUIBB CO Bristol-Myers Squibb Reports $48.194 Billion in Revenues for 2025, GAAP EPS Increases to $3.46

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
BRISTOL MYERS SQUIBB CO Bristol-Myers Squibb Reports 3% Revenue Growth to $12.2 Billion in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BRISTOL MYERS SQUIBB CO Bristol-Myers Squibb Reports Q2 2025 Revenue Growth to $12.27 Billion

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BRISTOL MYERS SQUIBB CO Bristol-Myers Squibb Reports $11.2 Billion Revenue in Q1 2025, Net Earnings Recovery

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BRISTOL MYERS SQUIBB CO Bristol-Myers Squibb Reports 8% Revenue Growth, Net Loss Due to Acquisition-Related Charges and Restructuring Costs

Via official filing (AI summary) | over 1 year ago | 0 comments